Research
Categories
Predictors of Resistance Emergence Evaluation in Multidrug Resistant-Tuberculosis Patients on Treatment (PREEMPT)
Principal Investigators
:
Dr Amrose Pradeep, Dr R Balakrishnan
Funding Agency
:
Division Of Microbiology and Infectious diseases, NIH.
Collaborators
:
Brown University
FCRA
Ongoing
Clinical
Objectives:
- Determine whether low serum antimycobacterial drug concentrations are associated with the clinical emergence of drug resistance in MDR-TB patients.
- Determine whether HIV seropositivity is a risk factor for low serum drug concentrations.
- Determine the contribution of increased DNA mutation to clinical emergence of drug resistance in patient isolates.
- Determine the earliest time at which mutations responsible for drug resistance can be detected during treatment.
- Determine the earliest time at which mutations responsible for drug resistance can be detected during treatment
Abstract:
The study will enroll 400 patients with MDR-TB in India and Brazil over a 24-month period and follow them prospectively for 3 years to evaluate the predictors of Resistance Emergence Evaluation in MDR-TB Patients on Treatment.The study will be for a total duration of 5 years. Patients who are MDR TB will be enrolled in the study when they start their MDR TB treatment and followed up for a period of 12 months after completion of their MDR TB treatment.
